Lancet . 2011; RADIANT-2; Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2) a randomised, placeb
Lancet . 2011; RADIANT-2; Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2) a randomised, placeb
همه حقوق این وبسایت متعلق به داروسـازی دکتـر عبیدی است. © 1404
نظرات کاربران